Terazosin AND Prostatitis

[J Dimitrakov]

The Journal of Urology 2003; 169(2):592-596
Terazosin Therapy For Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Randomized, Placebo Controlled Trial

PHAIK YEONG CHEAH*; MEN LONG LIONG; KAH HAY YUEN; CHU LEONG TEH; TIMOTHY KHOR; JIN RONG YANG; HIN WAI YAP; JOHN N. KRIEGER" 

Purpose:

We evaluate terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome.

Materials and Methods:

The study included 100, 20 to-50-year-old subjects who met the consensus criteria for chronic prostatitis/chronic pelvic pain syndrome and had not received previous alpha-blockers. Subjects were randomized to receive terazosin with dose escalation from 1 to 5 mg. daily or placebo for 14 weeks. The primary criterion for response was scoring 2 or less ("delighted-to-mostly satisfied") on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) quality of life item. The secondary criterion for response was greater than 50% reduction in NIH-CPSI pain score at 14 weeks. Other outcomes included total and NIH-CPSI domain scores, International Prostate Symptom Score, peak urinary flow rate, post-void residual urine and adverse effects.

Results:

Using the primary criterion 24 of 43 evaluable subjects (56%) responded in the terazosin group compared to 14 of 43 (36%) in the placebo group (p = 0.03). Using the secondary criterion 26 of 43 subjects (60%) responded in the terazosin group compared to 16 of 43 (37%) in the placebo group (p = 0.03). The terazosin group had greater reductions (p <0.05) in NIH-CPSI total score, individual domain scores and International Prostate Symptom Score than the placebo group. There was no difference in peak urinary flow rate or post-void residual. In the terazosin group 18 patients (42%) had side effects compared to 9 (21%) in the placebo group (p = 0.04).

Conclusions:

Terazosin proved superior to placebo for patients with chronic prostatitis/chronic pelvic pain syndrome who had not received alpha-blockers previously.

Key Words: prostate; chronic disease; pelvic pain; prostatitis; drug therapy
From the School of Pharmaceutical Sciences, University of Science Malaysia, Department of Urology, Lam Wah Ee Hospital, Department of Urology, Penang Adventist Hospital, Department of Urology, Gleneagles Medical Center, Department of Urology, Penang Hospital, Department of Urology, Island Hospital, Penang, Malaysia, and the Department of Urological Surgery, University of Washington School of Medicine, Seattle, Washington

Accepted for publication August 16, 2002.

"  Requests for reprints: Department of Urological Surgery, University of Washington School of Medicine, VA Puget Sound Health Care System, 1660 S. Columbian Way, Seattle, Washington 98108.

Supported by an unrestricted grant from Abbott Laboratories, Malaysia.

The Journal of Urology 2003; 169(2):592-596
Copyright © 2003 Lippincott Williams & Wilkins
All rights reserved

[webslave]

This study gives alpha-blockers the :thumbup:

This is in line with stories men are posting on this site. Many men like what Flomax is doing for them.

I wonder if the big Flomax/antibiotic study will support this?

[latte]

Yes, Flomax does make it easier to pee but does not address the real issue of inflammation that is unknown in origin. My prostate still feels inflamed and painful and the Flomax does nothing to alleviate that part of CPPS. It does help the flow and relax the urinary "tightness" for me.

[webslave]

Some men do not have issues with urination (frequency, difficulty etc), and for them Flomax is perhaps not helpful.